US pharmaceutical giant Pfizer continues to feed its hunger for acquisitions by agreeing to acquire cancer drug producer Medivation for $14bn

Following the failed acquisition of AstraZeneca last year, Pfizer has unveiled plans to buy Hospira in a deal that will bring the company to the forefront of biotech medicine